A Phase 4 interventional study of Rebif® in Multiple Sclerosis and Relapsing-Remitting, sponsored by Merck KGaA, Darmstadt, Germany. Completed at 14 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-08-24.
Sponsored by Merck KGaA, Darmstadt, Germany · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies testing Interferon beta-1a in Multiple Sclerosis — none open to participants now, none under way, none of them phase 3. Interferon beta-1a · Multiple Sclerosis.
Among the 34 studies testing Interferon beta-1a in Multiple Sclerosis, this one is the 17th largest by enrollment, is the only one that started in 2013, is one of 15 in phase 4, and was the 29th registered.
3,271 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.
Browse Multiple Sclerosis studies →None of the 34 studies testing Interferon beta-1a in Multiple Sclerosis is open now. The open studies under Multiple Sclerosis, anywhere →
Interferon beta-1a: first FDA approval 1996 (AVONEX), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →
Of the 433 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6 · Phase 3 8 · Phase 4 15
First in 1999; this study’s year is marked. 1 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 93 is above the median of 50 across 2,207 interventional studies indexed under Multiple Sclerosis.
Median enrollment 85 across the 34 interventional studies. Of the 32 that completed or were terminated, 16 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 34 have an industry lead sponsor. The 10 most frequent:
Merck KGaA, Darmstadt, Germany is the lead sponsor of 275 studies on the registry; none are open to participants now.
71 studies in Multiple Sclerosis by Merck KGaA, Darmstadt, Germany: none open now, 1 under way, none of them phase 3. Of 70 finished, 42 (60%) have results posted.
Among the 71 studies in Multiple Sclerosis by Merck KGaA, Darmstadt, Germany, this one is the 25th largest by enrollment of the 33 interventional ones that give a count, is one of 3 that started in 2013, is one of 11 in phase 4, and was the 49th registered.
Merck KGaA, Darmstadt, Germany’s Multiple Sclerosis studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 34 studies testing Interferon beta-1a in Multiple Sclerosis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck KGaA, Darmstadt, Germany’s 71 in Multiple Sclerosis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a randomized, comparative, and multicenter study to assess the impact of a patient support program (MinSupport Plus) on health related quality of life (HRQoL) and adherence in subjects with relapsing-remitting multiple sclerosis administered Rebif® with the RebiSmart™ device.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will be administered Rebif® by the RebiSmart™ device at a dose of either 22 or 44 microgram (mcg) subcutaneously (SC) 3 times a week in accordance to the summary of product characteristics (SPC) along with technical support for RebiSmart.
Drug: Rebif®
Subjects will be administered Rebif® by the RebiSmart™ device at a dose of either 22 or 44 mcg SC 3 times a week in accordance to the SPC along with subject support program MinSupport Plus which includes technical support for RebiSmart™ device, personal coaching regarding treatment and understanding of the disease, lifestyle guide and web support.
Drug: Rebif®
Change From Baseline in Multiple Sclerosis Impact Scale-29 (MSIS-29) Psychological Score at Month 12
Multiple Sclerosis Impact Scale-29 (MSIS-29) is a validated MS specific questionnaire consisting of 29 questions of which 20 addressed the physical impact component and 9 assessed the psychological impact. A combined score can be generated, or both components can be reported separately. The psychological wellbeing assessment portion of the MSIS-29 was comprised of 9 questions in which subjects rate the impact of MS on their day-to-day life from 1=no impact to 5=extreme impact. The total Psychological Score was calculated using following formula: sum of score for 9 questions - 9/0.36. The total score range ranges from 0-100 where, lower total score indicates less psychologically-related impact while a higher total score indicates greater psychologically-related impact on a subject's functioning.
Time frame: Baseline and Month 12
Change From Baseline in Multiple Sclerosis Impact Scale-29 (MSIS-29) Psychological Score at Month 6
Multiple Sclerosis Impact Scale-29 (MSIS-29) is a validated MS specific questionnaire consisting of 29 questions of which 20 addressed the physical impact component and 9 assessed the psychological impact. A combined score can be generated, or both components can be reported separately. The psychological wellbeing assessment portion of the MSIS-29 was comprised of 9 questions in which subjects rate the impact of MS on their day-to-day life from 1=no impact to 5=extreme impact. The total Psychological Score was calculated using following formula: sum of score for 9 questions - 9/0.36. The total score range ranges from 0-100 where, lower total score indicates less psychologically-related impact while a higher total score indicates greater psychologically-related impact on a subject's functioning.
Time frame: Baseline and Month 6
Change From Baseline in Multiple Sclerosis Impact Scale-29 (MSIS-29) Total Score at Month 6 and 12
Multiple Sclerosis Impact Scale-29 (MSIS-29) is a validated MS specific questionnaire consisting of 29 questions of which 20 addressed the physical impact component and 9 assessed the psychological impact. A combined score can be generated, or both components can be reported separately. The total score of the MSIS-29 was comprised of all the 29 questions in which subjects rate the impact of MS on their day-to-day life from 1=no impact to 5=extreme impact. The total Score was calculated using following formula: sum of score for 29 questions - 29/1.45. The total score range ranges from 0-100 where, lower total score indicates less psychologically-related impact while a higher total score indicates greater psychologically-related impact on a subject's functioning.
Time frame: Baseline, Month 6 and 12
Change From Baseline in Euro Quality of Life Questionnaire With 5 Questions Alternatives (EQ5D-5L) Summary Score at Month 6 and 12
Quality of life was assessed using the EQ5D-5L score, which is one of the most widely used generic index measures of health-related quality of life. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension comprises 5 levels with corresponding numeric scores ranging from 1 (no problems) through 5 (extreme problems) in which 1= no problems, 2= slight problems, 3= moderate problems, 4= severe problems, and 5= extreme problems. A unique EQ5D-5L health state was defined by combining the numeric level scores for each of the 5 dimensions and the total score ranges from 5 to 25. An increase in the EQ5D-5L total score indicates worsening.
Time frame: Baseline, Month 6 and 12
Change From Baseline in Euro Quality of Life Questionnaire With 5 Questions Alternatives (EQ5D-5L) Visual Analogue Scale (VAS) Scale at Month 6 and 12
EQ-5D-5L VAS was used to record a subject's rating for his/her current health-related quality of life state and captured on a vertical VAS (0-100), where 0 = worst imaginable health state and 100 = best imaginable health state.
Time frame: Baseline, Month 6 and 12
Percentage of Subjects With Treatment Adherence at Month 6 and 12
According to the World Health Organisation (WHO), treatment adherence is defined as both compliance (taking the medication in the correct dose and according to the schedule prescribed) and persistency (maintenance of the drug regimen over the long-term). Percentage of subjects with \<10% missed injections (measured with the software RDS 2.0) during 6 and 12 months were reported.
Time frame: Month 6 and 12
Change From Baseline in Fatigue Severity Scale (FSS) Score at Month 6 and 12
Fatigue Severity Scale (FSS) is a method of evaluating fatigue in multiple sclerosis and is designed to differentiate fatigue from clinical depression, since both share some of the same symptoms. The Fatigue Severity Scale is a 9-item questionnaire developed to assess the level of fatigue due to neurological disease, were each assessed on a 1-7 scale (1= no fatigue and 7= severe fatigue). The total score was calculated as the average of individual 9-items and ranged from 1 to 7 with a higher value indicating greater impairment due to fatigue.
Time frame: Baseline, Month 6 and 12
Change From Baseline in Modified Fatigue Impact Scale Score at Month 6 and 12
The Modified Fatigue Impact Scale is a list of 21 statements describing how fatigue may affect a person's functioning. Answers ranging from 0 (Never) to 4 (Almost always). A total score ranged from a possible 0 (no fatigue impact) to 84 (almost always impacted by fatigue). A lower total score indicates less fatigue-related impact while a higher total score indicates greater fatigue-related impact on a subject's functioning.
Time frame: Baseline, Month 6 and 12
Change From Baseline in Modified Fatigue Impact Scale Index at Month 6 and 12
The Modified Fatigue Impact Index assesses fatigue- severity, distress, or degree of interference. Modified Fatigue Impact Scale Index was expressed in terms of percentage and ranged from 0% (no fatigue) to 100% (almost always impacted by fatigue).
Time frame: Baseline, Month 6 and 12
Change From Baseline in Hospital Anxiety and Depression Scale (HADS) Score at Month 6 and 12
Hospital Anxiety and Depression Scale (HADS) was used to measure depression and anxiety in patients. The scale was limited to 14 questions, a practical tool for identifying and quantifying the two most common forms psychological disturbances in medical subjects. 7 of the items relate to anxiety and 7 relate to depression. Each item on the questionnaire was scored from 0-3 giving a total score between 0 and 21 for either anxiety or depression where higher score indicates more anxiety/depression.
Time frame: Baseline, Month 6 and 12
Number of Subjects With Working Ability at Month 12
Working ability was assessed by measuring the number of subjects for the following categories: 1) Subjects with full sickness/disability pension, 2) Subjects who were employed or had their own business, 3) Subjects who were retired, 4) Subjects who were studying, 5) None of the above.
Time frame: Month 12
Percentage of Subjects With Adverse Events (AE) up to Month 12
AE was defined as any untoward medical occurrence which does not necessarily have a causal relationship with this the study drug. An AE was defined as any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. A serious AE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Treatment Emergent Adverse Events (TEAEs) include both Serious TEAEs and non-serious TEAEs.
Time frame: Baseline up to Month 12
Number of Subjects With Response Based on Lifestyle Questionnaire for (MinSupport Plus) at Month 6 and 12
Lifestyle Questionnaire was used to assess the quality of life for subjects based on following parameters: Stress, Alcohol, Cost, Physical Aspect, Sleep, Activity and Smoking. Subjects provided their responses on the basis of three color codes: Green, Orange and Red, where Green refers to - no problem; Orange refers to - some problem and red refers to - definite/debilitating problem.
Time frame: Month 6 and 12
Number of Subjects With Response Based on Subject Satisfaction Questionnaire at Month 12
The subject satisfaction questionnaire was defined as satisfaction with overall treatment and support from health care providers during the last 12 months. Subjects were asked to rate their satisfaction by choosing either "Very discontented, discontented, contented or Very contented".
Time frame: Month 12
Number of Subjects With Response Based on Health Care Personnel Satisfaction Questionnaire at Month 12
The subject satisfaction questionnaire was defined as satisfaction with overall treatment and support from health care providers during the last 12 months. Subjects were asked to rate their satisfaction by choosing either "Very unsatisfied, unsatisfied, satisfied or very satisfied".
Time frame: Month 12
Number of Subjects With Lifestyle Goals for MinSupport Plus at Month 12
Subjects defined up to 4 personal lifestyle goals during the first study week. Subjects completed the following questions related to lifestyle goals achieved during this study: 1. Was the goal achieved? (Yes/No) 2. If yes, better than expected or achieved as expected? 3. If better than expected, a lot or a little better than expected? 4. If no, a little or a lot less than expected?
Time frame: Month 12
| Milestone | Subject Support Program (MinSupport Plus) | Technical Support for the RebiSmart™ Device |
|---|---|---|
| Started | 46 | 47 |
| Intent to treat (itt) | 38 | 39 |
| Completed | 31 | 29 |
| Not completed | 15 | 18 |
| Withdrew: Adverse event | 5 | 7 |
| Withdrew: Insufficient clinical response | 10 | 10 |
| Withdrew: Laboratory abnormality | 0 | 1 |
Multiple Sclerosis Impact Scale-29 (MSIS-29) is a validated MS specific questionnaire consisting of 29 questions of which 20 addressed the physical impact component and 9 assessed the psychological impact. A combined score can be generated, or both components can be reported separately. The psychological wellbeing assessment portion of the MSIS-29 was comprised of 9 questions in which subjects rate the impact of MS on their day-to-day life from 1=no impact to 5=extreme impact. The total Psychological Score was calculated using following formula: sum of score for 9 questions - 9/0.36. The total score range ranges from 0-100 where, lower total score indicates less psychologically-related impact while a higher total score indicates greater psychologically-related impact on a subject's functioning.
| units on a scale | Subject Support Program (MinSupport Plus) | Technical Support for the RebiSmart™ Device |
|---|---|---|
| Baseline | 35.19 ± 24.38 | 30.48 ± 20.94 |
| Change at Month 12 | -2.44 ± 19.38 | -3.04 ± 19.76 |
Multiple Sclerosis Impact Scale-29 (MSIS-29) is a validated MS specific questionnaire consisting of 29 questions of which 20 addressed the physical impact component and 9 assessed the psychological impact. A combined score can be generated, or both components can be reported separately. The psychological wellbeing assessment portion of the MSIS-29 was comprised of 9 questions in which subjects rate the impact of MS on their day-to-day life from 1=no impact to 5=extreme impact. The total Psychological Score was calculated using following formula: sum of score for 9 questions - 9/0.36. The total score range ranges from 0-100 where, lower total score indicates less psychologically-related impact while a higher total score indicates greater psychologically-related impact on a subject's functioning.
| units on a scale | Subject Support Program (MinSupport Plus) | Technical Support for the RebiSmart™ Device |
|---|---|---|
| Baseline | 35.19 ± 24.38 | 30.48 ± 20.94 |
| Change at Month 6 | -1.36 ± 16.82 | -1.59 ± 13.26 |
Multiple Sclerosis Impact Scale-29 (MSIS-29) is a validated MS specific questionnaire consisting of 29 questions of which 20 addressed the physical impact component and 9 assessed the psychological impact. A combined score can be generated, or both components can be reported separately. The total score of the MSIS-29 was comprised of all the 29 questions in which subjects rate the impact of MS on their day-to-day life from 1=no impact to 5=extreme impact. The total Score was calculated using following formula: sum of score for 29 questions - 29/1.45. The total score range ranges from 0-100 where, lower total score indicates less psychologically-related impact while a higher total score indicates greater psychologically-related impact on a subject's functioning.
| units on a scale | Subject Support Program (MinSupport Plus) | Technical Support for the RebiSmart™ Device |
|---|---|---|
| Baseline | 21.81 ± 21.55 | 18.01 ± 16.61 |
| Change at Month 6 | 0.56 ± 9.35 | 0.14 ± 11.19 |
| Change at Month 12 | 1.00 ± 11.34 | 0.00 ± 10.45 |
Quality of life was assessed using the EQ5D-5L score, which is one of the most widely used generic index measures of health-related quality of life. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension comprises 5 levels with corresponding numeric scores ranging from 1 (no problems) through 5 (extreme problems) in which 1= no problems, 2= slight problems, 3= moderate problems, 4= severe problems, and 5= extreme problems. A unique EQ5D-5L health state was defined by combining the numeric level scores for each of the 5 dimensions and the total score ranges from 5 to 25. An increase in the EQ5D-5L total score indicates worsening.
| units on a scale | Subject Support Program (MinSupport Plus) | Technical Support for the RebiSmart™ Device |
|---|---|---|
| Baseline | 8.84 ± 3.37 | 8.03 ± 2.30 |
| Change at Month 6 | 0.18 ± 2.17 | 0.10 ± 1.76 |
| Change at Month 12 | 0.05 ± 2.51 | -0.08 ± 1.86 |
EQ-5D-5L VAS was used to record a subject's rating for his/her current health-related quality of life state and captured on a vertical VAS (0-100), where 0 = worst imaginable health state and 100 = best imaginable health state.
| units on a scale | Patient Support Program (MinSupport Plus) | Technical Support for the RebiSmart™ Device |
|---|---|---|
| Baseline | 71.18 ± 20.70 | 71.49 ± 16.61 |
| Change at Month 6 | -0.71 ± 11.36 | -3.38 ± 19.35 |
| Change at Month 12 | -0.84 ± 16.07 | -2.31 ± 20.60 |
According to the World Health Organisation (WHO), treatment adherence is defined as both compliance (taking the medication in the correct dose and according to the schedule prescribed) and persistency (maintenance of the drug regimen over the long-term). Percentage of subjects with \<10% missed injections (measured with the software RDS 2.0) during 6 and 12 months were reported.
| Percentage of Subjects | Subject Support Program (MinSupport Plus) | Technical Support for the RebiSmart™ Device |
|---|---|---|
| At Month 6 | 71.05 | 64.10 |
| At Month 12 | 65.79 | 53.85 |
Fatigue Severity Scale (FSS) is a method of evaluating fatigue in multiple sclerosis and is designed to differentiate fatigue from clinical depression, since both share some of the same symptoms. The Fatigue Severity Scale is a 9-item questionnaire developed to assess the level of fatigue due to neurological disease, were each assessed on a 1-7 scale (1= no fatigue and 7= severe fatigue). The total score was calculated as the average of individual 9-items and ranged from 1 to 7 with a higher value indicating greater impairment due to fatigue.
| units on a scale | Subject Support Program (MinSupport Plus) | Technical Support for the RebiSmart™ Device |
|---|---|---|
| Baseline | 3.93 ± 1.75 | 3.98 ± 1.72 |
| Change at Month 6 | 0.15 ± 0.79 | 0.05 ± 0.81 |
| Change at Month 12 | 0.13 ± 0.89 | 0.08 ± 1.09 |
The Modified Fatigue Impact Scale is a list of 21 statements describing how fatigue may affect a person's functioning. Answers ranging from 0 (Never) to 4 (Almost always). A total score ranged from a possible 0 (no fatigue impact) to 84 (almost always impacted by fatigue). A lower total score indicates less fatigue-related impact while a higher total score indicates greater fatigue-related impact on a subject's functioning.
| units on a scale | Subject Support Program (MinSupport Plus) | Technical Support for the RebiSmart™ Device |
|---|---|---|
| Baseline | 29.74 ± 20.50 | 31.08 ± 19.08 |
| Change at Month 6 | 3.89 ± 10.81 | 2.27 ± 9.78 |
| Change at Month 12 | 3.75 ± 10.43 | 1.78 ± 10.65 |
The Modified Fatigue Impact Index assesses fatigue- severity, distress, or degree of interference. Modified Fatigue Impact Scale Index was expressed in terms of percentage and ranged from 0% (no fatigue) to 100% (almost always impacted by fatigue).
| Percentage of fatigue | Patient Support Program (MinSupport Plus) | Technical Support for the RebiSmart™ Device |
|---|---|---|
| Baseline | 35.40 ± 24.41 | 37.00 ± 22.72 |
| Change at Month 6 | 4.63 ± 12.87 | 2.71 ± 11.64 |
| Change at Month 12 | 4.47 ± 12.42 | 2.12 ± 12.68 |
Hospital Anxiety and Depression Scale (HADS) was used to measure depression and anxiety in patients. The scale was limited to 14 questions, a practical tool for identifying and quantifying the two most common forms psychological disturbances in medical subjects. 7 of the items relate to anxiety and 7 relate to depression. Each item on the questionnaire was scored from 0-3 giving a total score between 0 and 21 for either anxiety or depression where higher score indicates more anxiety/depression.
| units on a scale | Subject Support Program (MinSupport Plus) | Technical Support for the RebiSmart™ Device |
|---|---|---|
| Baseline (Anxiety Score) | 6.13 ± 4.14 | 5.62 ± 3.21 |
| Change at Month 6 (Anxiety Score) | -0.21 ± 2.92 | -0.56 ± 2.78 |
| Change at Month 12 (Anxiety Score) | -0.42 ± 3.48 | -0.18 ± 3.26 |
| Baseline (Depression Score) | 4.26 ± 3.49 | 3.72 ± 2.77 |
| Change at Month 6 (Depression Score) | 0.61 ± 2.43 | 0.46 ± 2.85 |
| Change at Month 12 (Depression Score) | 0.42 ± 3.61 | 0.74 ± 3.14 |
Working ability was assessed by measuring the number of subjects for the following categories: 1) Subjects with full sickness/disability pension, 2) Subjects who were employed or had their own business, 3) Subjects who were retired, 4) Subjects who were studying, 5) None of the above.
| Subjects | Subject Support Program (MinSupport Plus) | Technical Support for the RebiSmart™ Device |
|---|---|---|
| Subjects with full sickness/disability pension | 4 | 5 |
| Subjects who were employed or had own business | 22 | 25 |
| Subject who were retired | 2 | 2 |
| Subject who were studying | 3 | 2 |
| None of the above | 1 | 1 |
AE was defined as any untoward medical occurrence which does not necessarily have a causal relationship with this the study drug. An AE was defined as any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. A serious AE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Treatment Emergent Adverse Events (TEAEs) include both Serious TEAEs and non-serious TEAEs.
| Percentage of Subjects | Subject Support Program (MinSupport Plus) | Technical Support for the RebiSmart™ Device |
|---|---|---|
| Percentage of Subjects With Adverse Events (AE) up to Month 12 | 45.7 | 61.7 |
Lifestyle Questionnaire was used to assess the quality of life for subjects based on following parameters: Stress, Alcohol, Cost, Physical Aspect, Sleep, Activity and Smoking. Subjects provided their responses on the basis of three color codes: Green, Orange and Red, where Green refers to - no problem; Orange refers to - some problem and red refers to - definite/debilitating problem.
| Subjects | Subject Support Program (MinSupport Plus) |
|---|---|
| Month 6: Stress: Green; n= 30 | 2 |
| Month 6: Stress: Orange; n= 30 | 3 |
| Month 6: Stress: Red; n= 30 | 3 |
| Month 12: Stress: Green; n= 31 | 3 |
| Month 12: Stress: Orange; n= 31 | 2 |
| Month 12: Stress: Red; n= 31 | 2 |
| Month 6: Alcohol: Green; n= 30 | 7 |
| Month 6: Alcohol: Orange; n= 30 | 1 |
| Month 6: Alcohol: Red; n= 30 | 1 |
| Month 12: Alcohol: Green; n= 32 | 6 |
| Month 12: Alcohol: Orange; n= 32 | 6 |
| Month 12: Alcohol: Red; n= 32 | 6 |
| Month 6: Cost: Green; n= 30 | 4 |
| Month 6: Cost: Orange; n= 30 | 4 |
| Month 6: Cost: Red; n= 30 | 4 |
| Month 12: Cost: Green; n= 32 | 3 |
| Month 12: Cost: Orange; n= 32 | 3 |
| Month 12: Cost: Red; n= 32 | 3 |
| Month 6: Physical: Green; n= 30 | 5 |
| Month 6: Physical: Orange; n= 30 | 2 |
| Month 6: Physical: Red; n= 30 | 1 |
| Month 12: Physical: Green; n= 32 | 5 |
| Month 12: Physical: Orange; n= 32 | 1 |
| Month 12: Physical: Red; n= 32 | 1 |
| Month 6: Activity: Green; n= 30 | 5 |
| Month 6: Activity: Orange; n= 30 | 2 |
| Month 6: Activity: Red; n= 30 | 1 |
| Month 12: Activity: Green; n= 32 | 5 |
| Month 12: Activity: Orange; n= 32 | 1 |
| Month 12: Activity: Red; n= 32 | 1 |
| Month 6: Sleep: Green; n= 30 | 3 |
| Month 6: Sleep: Orange; n= 30 | 4 |
| Month 6: Sleep: Red; n= 30 | 1 |
| Month 12: Sleep: Green; n= 32 | 3 |
| Month 12: Sleep: Orange; n= 32 | 2 |
| Month 12: Sleep: Red; n= 32 | 1 |
| Month 6: Smoking: Green; n= 31 | 5 |
| Month 6: Smoking: Orange; n= 31 | 1 |
| Month 6: Smoking: Red; n= 31 | 1 |
| Month 12: Smoking: Green; n= 32 | 5 |
| Month 12: Smoking: Orange; n= 32 | 1 |
| Month 12: Smoking: Red; n= 32 | 1 |
The subject satisfaction questionnaire was defined as satisfaction with overall treatment and support from health care providers during the last 12 months. Subjects were asked to rate their satisfaction by choosing either "Very discontented, discontented, contented or Very contented".
| Subjects | Subject Support Program (MinSupport Plus) | Technical Support for the RebiSmart™ Device |
|---|---|---|
| Very discontented | 1 | 2 |
| Discontented | 6 | 5 |
| Contented | 13 | 11 |
| Very contented | 10 | 15 |
The subject satisfaction questionnaire was defined as satisfaction with overall treatment and support from health care providers during the last 12 months. Subjects were asked to rate their satisfaction by choosing either "Very unsatisfied, unsatisfied, satisfied or very satisfied".
| Subjects | Subject Support Program (MinSupport Plus) | Technical Support for the RebiSmart™ Device |
|---|---|---|
| Very unsatisfied | 0 | 1 |
| Unsatisfied | 2 | 0 |
| Satisfied | 10 | 9 |
| Very satisfied | 6 | 3 |
Subjects defined up to 4 personal lifestyle goals during the first study week. Subjects completed the following questions related to lifestyle goals achieved during this study: 1. Was the goal achieved? (Yes/No) 2. If yes, better than expected or achieved as expected? 3. If better than expected, a lot or a little better than expected? 4. If no, a little or a lot less than expected?
| Subjects | Subject Support Program (MinSupport Plus) |
|---|---|
| Goal 1(G1) : Goal Achieved; n= 38 | 18 |
| G1: Goal not Achieved; n= 38 | 4 |
| G1: Missing; n= 38 | 16 |
| G1 Achieved: Better than Expected; n= 18 | 5 |
| G1 Achieved: As Expected; n= 18 | 10 |
| G1 Achieved: Missing; n= 18 | 3 |
| G1Acheived:Better than Expected:Little Better;n= 5 | 4 |
| G1Achieved:Better than expected:Lot better; n= 5 | 0 |
| G1Achieved:Better than Expected: Missing; n= 5 | 1 |
| G1 not Achieved: Little Less; n= 4 | 1 |
| G1 not Achieved: Lot Less; n= 4 | 0 |
| G1 not Achieved: Missing; n= 4 | 3 |
| Goal 2 (G2): Goal Achieved; n= 38 | 3 |
| G2: Goal not Achieved; n= 38 | 1 |
| G2: Missing; n= 38 | 34 |
| G2 Achieved: Better than Expected; n= 3 | 2 |
| G2 Achieved: As Expected; n= 3 | 0 |
| G2 Achieved: Missing; n= 3 | 1 |
| G2Achieved:Better than Expected:Little Better;n= 2 | 1 |
| G2 Achieved: Better than Expected:Lot Better; n= 2 | 1 |
| G2 Achieved: Better than Expected: Missing; n= 2 | 0 |
| G2 not Achieved: Little Less; n= 1 | 0 |
| G2 not Achieved: Lot Less; n= 1 | 1 |
| G2 not Achieved: Missing; n= 1 | 0 |
| Goal 3 (G3): Goal Achieved; n= 38 | 0 |
| G3: Goal not Achieved; n= 38 | 1 |
| G3: Missing; n= 38 | 37 |
| G3 Achieved: As Expected; n= 0 | 0 |
| G3 Achieved: Better than Expected; n= 0 | 0 |
| G3 Achieved: Missing; n= 0 | 0 |
| G3 Achieved:Better than Expected:Little Better;n=0 | 0 |
| G3 Achieved:Better than Expected: Lot Better;n=0 | 0 |
| G3 Achieved: Better than Expected: Missing; n= 0 | 0 |
| G3 not Achieved: Little Less; n= 1 | 1 |
| G3 not Achieved: Lot Less; n= 1 | 0 |
| G3 not Achieved: Missing; n= 1 | 0 |
| Goal 4 (G4): Goal Achieved; n= 38 | 0 |
| G4: Goal not Achieved; n= 38 | 1 |
| G4: Missing; n= 38 | 37 |
| G4 Achieved: Better than Expected; n= 0 | 0 |
| G4 Achieved: As Expected; n= 0 | 0 |
| G4 Achieved: Missing; n= 0 | 0 |
| G4 Expected:Little Better; n= 0 | 0 |
| G4Achieved:Better than expected:Lot Better; n= 0 | 0 |
| G4 Achieved: Better than Expected: Missing; n= 0 | 0 |
| G4 not Achieved: Little Less; n= 1 | 0 |
| G4 not Achieved: Lot Less; n= 1 | 0 |
| G4 not Achieved: Missing; n= 1 | 1 |
Collected over Baseline up to Month 12. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Patient Support Program (MinSupport Plus) | — | 2/46 (4.3%) | 19/46 (41.3%) |
| Technical Support for the RebiSmart™ Device | — | 0/47 (0%) | 29/47 (61.7%) |
| Event | Patient Support Program (MinSupport Plus) | Technical Support for the RebiSmart™ Device |
|---|---|---|
| Urinary tract infectionInfections and infestations | 2/46 | 0/47 |
| PneumoniaInfections and infestations | 1/46 | 0/47 |
| Event | Patient Support Program (MinSupport Plus) | Technical Support for the RebiSmart™ Device |
|---|---|---|
| Hepatic enzyme increasedInvestigations | 1/46 | 5/47 |
| HeadacheNervous system disorders | 2/46 | 3/47 |
| Administration site painGeneral disorders | 2/46 | 0/47 |
| FatigueGeneral disorders | 2/46 | 1/47 |
| Influenza like illnessGeneral disorders | 2/46 | 2/47 |
| NasopharyngitisInfections and infestations | 2/46 | 1/47 |
| Urinary tract infectionInfections and infestations | 2/46 | 0/47 |
| Multiple sclerosis relapseNervous system disorders | 2/46 | 2/47 |
| InsomniaPsychiatric disorders | 2/46 | 0/47 |
| DepressionPsychiatric disorders | 1/46 | 2/47 |
The Intent-to-Treat (ITT) population included all subjects randomized into the trial and have completed at least 1 post-baseline assessment of the questionnaires.
| Age, Customized(Participants) | Subject Support Program (MinSupport Plus) | Technical Support for the RebiSmart™ Device | Total |
|---|---|---|---|
| Between 18 to 72 years | 38 | 39 | 77 |
| Greater than (>) 72 years | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Subject Support Program (MinSupport Plus) | Technical Support for the RebiSmart™ Device | Total |
|---|---|---|---|
| Female | 24 | 24 | 48 |
| Male | 14 | 15 | 29 |
Ran from Feb 2013 to primary completion in Feb 2016, 36 months.
Results were first posted in Jul 2017, 1 year 4 months after primary completion.
Of 36 industry-sponsored phase 4 interventional studies under Multiple Sclerosis, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 37. This study's 36 months is above that.
Counting every sponsor, half of 69 studies reached it within 34 months; a quarter within 23 and three quarters within 59.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Interferon beta-1a
Merck KGaA, Darmstadt, Germany →